SinoMab BioScience Limited

Getting company information...

Press Releases by SinoMab BioScience Limited
Filter by year Year
All
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis

Apr 09, 2025 14:49 HKT/SGT

- Potentially a First-and Best-in-Class Product
- Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety Profile

中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果

Apr 09, 2025 14:41 HKT/SGT

- 有望成為全球首個兼具快速深度止癢、顯著皮損清除及
- 良好安全性的同類最優藥物

中国抗体制药有限公司SM17治疗特应性皮炎1b期概念验证临床试验取得突破性结果

Apr 09, 2025 14:30 HKT/SGT

- 有望成为全球首个兼具快速深度止痒、显著皮损清除及
- 良好安全性的同类最优药物

中国抗体SM17治疗特应性皮炎（AD）之临床前结果刊登于国际科学期刊《Allergy》

Apr 16, 2024 17:48 HKT/SGT

验证其治疗AD疗效与JAK1抑制剂相当耐受性安全性俱佳

中國抗體SM17治療特應性皮炎（AD）之臨床前結果刊登於國際科學期刊《Allergy》

Apr 16, 2024 17:44 HKT/SGT

驗證其治療AD療效與JAK1抑制劑相當耐受性安全性俱佳

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

Apr 16, 2024 17:35 HKT/SGT

Confirmed that the therapeutic efficacy of SM17 for treating AD is comparable to that of JAK1 inhibitor with good tolerability and safety

中国抗体SM17新药研究申请再获国家药监局批准

Sep 12, 2023 09:50 HKT/SGT

即将启动针对治疗特应性皮炎的临床开发计划

中國抗體SM17新藥研究申請再獲國家藥監局批准

Sep 12, 2023 09:49 HKT/SGT

即將啟動針對治療特應性皮炎的臨床開發計劃

SinoMab's IND Application of SM17 has once again Received Approval from NAMP

Sep 12, 2023 09:48 HKT/SGT

Clinical Development Program for the Treatment of AD to be Initiated Shortly

中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准

Aug 14, 2023 21:12 HKT/SGT

国内临床试验将加速开启

中國抗體SM17針對治療哮喘疾病的新藥研究申請獲國家藥監局批准

Aug 14, 2023 21:11 HKT/SGT

國內臨床試驗將加速開啟

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

Aug 14, 2023 21:10 HKT/SGT

Speeding up Domestic Clinical Trials

中国抗体SM17再增一项适应症研究申请针对治疗特应性皮炎（AD）的新药研究申请获国家药监局药品审评中心受理

Jun 12, 2023 20:45 HKT/SGT

中國抗體SM17再增一項適應症研究申請針對治療特應性皮炎（AD）的新藥研究申請獲國家藥監局藥品審評中心受理

Jun 12, 2023 20:44 HKT/SGT

SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE

Jun 12, 2023 20:43 HKT/SGT

中国抗体SM17针对治疗哮喘的新药研究申请获国家药监局药品审评中心受理

May 22, 2023 10:22 HKT/SGT

加快推进国内临床试验剑指哮喘药品蓝海

中國抗體SM17針對治療哮喘的新藥研究申請獲國家藥監局藥品審評中心受理

May 22, 2023 10:21 HKT/SGT

加快推進國內臨床試驗劍指哮喘藥品藍海

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

May 22, 2023 10:20 HKT/SGT

Accelerating Domestic Clinical Trials and Targeting the Blue Ocean of Asthma Drugs

SinoMab BioScience Limited

SinoMab BioScience Limited

SinoMab BioScience Limited

Press Releases by SinoMab BioScience LimitedFilter by year Year All2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

Apr 09, 2025 14:49 HKT/SGT

Apr 09, 2025 14:41 HKT/SGT

Apr 09, 2025 14:30 HKT/SGT

Apr 16, 2024 17:48 HKT/SGT

Apr 16, 2024 17:44 HKT/SGT

Apr 16, 2024 17:35 HKT/SGT

Sep 12, 2023 09:50 HKT/SGT

Sep 12, 2023 09:49 HKT/SGT

Sep 12, 2023 09:48 HKT/SGT

Aug 14, 2023 21:12 HKT/SGT

Aug 14, 2023 21:11 HKT/SGT

Aug 14, 2023 21:10 HKT/SGT

Jun 12, 2023 20:45 HKT/SGT

Jun 12, 2023 20:44 HKT/SGT

Jun 12, 2023 20:43 HKT/SGT

May 22, 2023 10:22 HKT/SGT

May 22, 2023 10:21 HKT/SGT

May 22, 2023 10:20 HKT/SGT

Dec 19, 2022 14:57 HKT/SGT

Dec 19, 2022 14:56 HKT/SGT

Press Releases by SinoMab BioScience Limited
Filter by year Year
All
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005